Table 1 General characteristics of the studied groups of women
Variable | Total N = 343 | HT study N = 76 | Raloxifene study N = 64 |
|---|---|---|---|
Age (years) | 62.40 ± 0.46 | 63.22 ± 1.00 | 65.30 ± 0.98 |
Body mass index (BMI) | 27.60 ± 0.08 | 27.30 ± 0.18 | 27.64 ± 0.17 |
BMD-FN (T-score) | −1.79 ± 0.03 | − 2.13 ± 0.04 | −2.16 ± 0.06 |
BMD-FN (g/cm2) | 0.65 ± 0.01 | 0.60 ± 0.01 | 0.60 ± 0.01 |
BMD-LS (T-score) | −2.37 ± 0.04 | −2.87 ± 0.04 | − 2.95 ± 0.05 |
BMD-LS (g/cm2) | 0.73 ± 0.01 | 0.68 ± 0.01 | 0.67 ± 0.01 |
Bone isoenzyme of alkaline phosphatase (μkat/l) | 0.56 ± 0.04 | 1.17 ± 0.11 | 0.68 ± 0.08 |
Osteocalcin (μg/l) | 3.85 ± 0.05 | 3.92 ± 0.11 | 4.25 ± 0.13 |
BetaCrosslaps (ng/l) | 709.65 ± 13.57 | 795.23 ± 24.21 | 876.86 ± 28.06 |
Serum calcium (mmol/l) | 2.40 ± 0.01 | 2.39 ± 0.02 | 2.46 ± 0.03 |
Serum phosphate (mmol/l) | 1.20 ± 0.01 | 1.19 ± 0.02 | 1.23 ± 0.03 |